GBT440-031 Sickle Cell Disease

Sickle Cell

Protocol:GBT440-031

Condition or Disease: Sickle Cell Disease

Study Type: Interventional (Clinical Trial)

Status: Enrollment Paused

Study Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT03036813

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Explore More News